|
US3932407A
(en)
|
1973-11-19 |
1976-01-13 |
Bristol-Myers Company |
Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
|
|
USRE31617E
(en)
|
1972-02-04 |
1984-06-26 |
Bristol-Myers Company |
Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
|
|
US4088753A
(en)
|
1975-04-16 |
1978-05-09 |
Parmer Laurence Pierpont |
Method of obtaining a splenic composition which inhibits platelet function and said composition
|
|
US4146718A
(en)
|
1978-04-10 |
1979-03-27 |
Bristol-Myers Company |
Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
|
|
US5387413A
(en)
|
1985-06-14 |
1995-02-07 |
The Research Foundation Of State University Of New York |
Method of inhibiting thrombus formation by the 7E3 monoclonal antibody
|
|
US5185323A
(en)
|
1988-03-31 |
1993-02-09 |
Temple University |
Suppression of megakaryocytopoiesis employing platelet factor 4 antimaturation factor
|
|
US5306709A
(en)
|
1991-11-15 |
1994-04-26 |
The University Of Pennsylvania |
Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
|
|
WO1993009794A1
(en)
|
1991-11-15 |
1993-05-27 |
University Of Pennsylvania |
Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
|
|
JP3670298B2
(ja)
|
1992-07-20 |
2005-07-13 |
大鵬薬品工業株式会社 |
スルホニウム化合物含有皮膚外用剤
|
|
US5604260A
(en)
|
1992-12-11 |
1997-02-18 |
Merck Frosst Canada Inc. |
5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
|
|
US5543297A
(en)
|
1992-12-22 |
1996-08-06 |
Merck Frosst Canada, Inc. |
Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
|
|
GB9602877D0
(en)
|
1996-02-13 |
1996-04-10 |
Merck Frosst Canada Inc |
3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
|
|
US5474995A
(en)
|
1993-06-24 |
1995-12-12 |
Merck Frosst Canada, Inc. |
Phenyl heterocycles as cox-2 inhibitors
|
|
HUT74986A
(en)
|
1994-01-10 |
1997-03-28 |
Merck Frosst Canada Inc |
Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them
|
|
US5521213A
(en)
|
1994-08-29 |
1996-05-28 |
Merck Frosst Canada, Inc. |
Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
|
|
JPH10507765A
(ja)
|
1994-10-27 |
1998-07-28 |
メルク フロスト カナダ インコーポレーテツド |
シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
|
|
US5552422A
(en)
|
1995-01-11 |
1996-09-03 |
Merck Frosst Canada, Inc. |
Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5691374A
(en)
|
1995-05-18 |
1997-11-25 |
Merck Frosst Canada Inc. |
Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
|
|
US5604253A
(en)
|
1995-05-22 |
1997-02-18 |
Merck Frosst Canada, Inc. |
N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
|
|
US5639780A
(en)
|
1995-05-22 |
1997-06-17 |
Merck Frosst Canada, Inc. |
N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
|
|
US5643933A
(en)
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
|
US5789413A
(en)
|
1996-02-01 |
1998-08-04 |
Merck Frosst Canada, Inc. |
Alkylated styrenes as prodrugs to COX-2 inhibitors
|
|
US5733909A
(en)
|
1996-02-01 |
1998-03-31 |
Merck Frosst Canada, Inc. |
Diphenyl stilbenes as prodrugs to COX-2 inhibitors
|
|
GB9607503D0
(en)
|
1996-04-11 |
1996-06-12 |
Merck Frosst Canada Inc |
Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
|
|
US5922742A
(en)
|
1996-04-23 |
1999-07-13 |
Merck Frosst Canada |
Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
|
|
US5677318A
(en)
|
1996-07-11 |
1997-10-14 |
Merck Frosst Canada, Inc. |
Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
|
|
US5861419A
(en)
|
1996-07-18 |
1999-01-19 |
Merck Frosst Canad, Inc. |
Substituted pyridines as selective cyclooxygenase-2 inhibitors
|
|
US7288266B2
(en)
|
1996-08-19 |
2007-10-30 |
United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
US20030073640A1
(en)
|
1997-07-23 |
2003-04-17 |
Ribozyme Pharmaceuticals, Inc. |
Novel compositions for the delivery of negatively charged molecules
|
|
US20030083272A1
(en)
|
1997-09-19 |
2003-05-01 |
Lahive & Cockfield, Llp |
Sense mrna therapy
|
|
US5898077A
(en)
*
|
1997-10-07 |
1999-04-27 |
Matsumoto Yushi-Seiyaku Co., Ltd. |
Process for preparation of an ester
|
|
DE69815707T2
(de)
|
1997-11-20 |
2004-07-01 |
Vical, Inc., San Diego |
Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
|
|
KR100358276B1
(ko)
|
1998-03-24 |
2002-10-25 |
닛폰 유시 가부시키가이샤 |
옥시란 유도체 및 이의 제조방법
|
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
|
US8206749B1
(en)
|
1999-02-26 |
2012-06-26 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
|
WO2001023002A1
(en)
|
1999-09-30 |
2001-04-05 |
National Jewish Medical And Research Center |
Method for inhibition of pathogenic microorganisms
|
|
US7060291B1
(en)
|
1999-11-24 |
2006-06-13 |
Transave, Inc. |
Modular targeted liposomal delivery system
|
|
JP2002069821A
(ja)
|
2000-08-28 |
2002-03-08 |
Teijin Ltd |
人工皮革用長繊維不織布の製造方法
|
|
US20040142474A1
(en)
|
2000-09-14 |
2004-07-22 |
Expression Genetics, Inc. |
Novel cationic lipopolymer as a biocompatible gene delivery agent
|
|
US6696038B1
(en)
|
2000-09-14 |
2004-02-24 |
Expression Genetics, Inc. |
Cationic lipopolymer as biocompatible gene delivery agent
|
|
US7708915B2
(en)
|
2004-05-06 |
2010-05-04 |
Castor Trevor P |
Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
|
|
US6652886B2
(en)
|
2001-02-16 |
2003-11-25 |
Expression Genetics |
Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
|
|
DE10109897A1
(de)
|
2001-02-21 |
2002-11-07 |
Novosom Ag |
Fakultativ kationische Liposomen und Verwendung dieser
|
|
CA2449054C
(en)
|
2001-05-30 |
2011-01-04 |
The Scripps Research Institute |
Integrin targeting liposome for nucleic acid delivery
|
|
ATE490267T1
(de)
|
2001-06-05 |
2010-12-15 |
Curevac Gmbh |
Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
|
|
EP1412065A2
(en)
|
2001-07-27 |
2004-04-28 |
President And Fellows Of Harvard College |
Laminar mixing apparatus and methods
|
|
DE10207178A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Komponenten für die Herstellung amphoterer Liposomen
|
|
US20050222064A1
(en)
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
|
US20050152980A1
(en)
|
2002-03-13 |
2005-07-14 |
Michael Ausborn |
Pharmeutical microparticles
|
|
US7901708B2
(en)
|
2002-06-28 |
2011-03-08 |
Protiva Biotherapeutics, Inc. |
Liposomal apparatus and manufacturing methods
|
|
EP1675614A2
(en)
|
2003-10-11 |
2006-07-05 |
Inex Pharmaceuticals Corp. |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
|
CN100423778C
(zh)
|
2003-11-25 |
2008-10-08 |
上海复旦张江生物医药股份有限公司 |
用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
|
|
US20050143336A1
(en)
|
2003-12-30 |
2005-06-30 |
Board Of Regents, The University Of Texas System |
Methods and compositions for improved non-viral gene therapy
|
|
US7799565B2
(en)
|
2004-06-07 |
2010-09-21 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering RNA
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
KR101146160B1
(ko)
|
2004-06-30 |
2012-07-16 |
넥타르 테라퓨틱스 |
중합체인자 ｉｘ 부분의 접합체
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
JP5042863B2
(ja)
|
2005-02-14 |
2012-10-03 |
サーナ・セラピューティクス・インコーポレイテッド |
生物学的に活性な分子をデリバリーするための脂質ナノ粒子系組成物および方法
|
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
|
US20120021042A1
(en)
|
2005-09-15 |
2012-01-26 |
Steffen Panzner |
Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
|
|
US8231907B2
(en)
|
2006-03-21 |
2012-07-31 |
Morehouse School Of Medicine |
Nanoparticles for delivery of active agents
|
|
ES2776100T3
(es)
|
2006-03-31 |
2020-07-29 |
Massachusetts Inst Technology |
Sistema para el suministro dirigido de agentes terapéuticos
|
|
US8367113B2
(en)
|
2006-05-15 |
2013-02-05 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
|
EP3192788A1
(en)
|
2006-10-03 |
2017-07-19 |
Arbutus Biopharma Corporation |
Lipid containing formulations
|
|
WO2008073558A2
(en)
|
2006-10-05 |
2008-06-19 |
The Johns Hopkins University |
Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
|
|
US20100015218A1
(en)
|
2007-02-16 |
2010-01-21 |
Vasant Jadhav |
Compositions and methods for potentiated activity of biologically active molecules
|
|
US7943168B2
(en)
|
2007-03-05 |
2011-05-17 |
Washington University |
Nanoparticle delivery systems comprising a hydrophobic core and a lipid/surfactant layer comprising a membrane-lytic peptide
|
|
CA2686735A1
(en)
|
2007-05-04 |
2008-11-13 |
Mdrna, Inc. |
Amino acid lipids and uses thereof
|
|
US9144546B2
(en)
|
2007-08-06 |
2015-09-29 |
Clsn Laboratories, Inc. |
Nucleic acid-lipopolymer compositions
|
|
US20090042825A1
(en)
|
2007-08-06 |
2009-02-12 |
Majed Matar |
Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
|
|
CA2695420A1
(en)
|
2007-08-23 |
2009-02-26 |
Novartis Ag |
Methods for detecting oligonucleotides
|
|
EP2630966B1
(en)
|
2007-10-12 |
2017-04-19 |
Massachusetts Institute of Technology |
Vaccine nanotechnology
|
|
US20090196917A1
(en)
|
2008-02-01 |
2009-08-06 |
University Of Kentucky Research Foundation |
Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
US8697098B2
(en)
|
2011-02-25 |
2014-04-15 |
South Dakota State University |
Polymer conjugated protein micelles
|
|
JP2012501965A
(ja)
|
2008-06-16 |
2012-01-26 |
バインド バイオサイエンシズ インコーポレイテッド |
薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
|
|
WO2010005740A2
(en)
|
2008-06-16 |
2010-01-14 |
Bind Biosciences, Inc. |
Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
|
|
US20110224447A1
(en)
|
2008-08-18 |
2011-09-15 |
Bowman Keith A |
Novel Lipid Nanoparticles and Novel Components for Delivery of Nucleic Acids
|
|
CN104119242B
(zh)
|
2008-10-09 |
2017-07-07 |
泰米拉制药公司 |
改善的氨基脂质和递送核酸的方法
|
|
ES2646630T3
(es)
|
2008-11-07 |
2017-12-14 |
Massachusetts Institute Of Technology |
Lipidoides aminoalcohólicos y usos de los mismos
|
|
HUE037082T2
(hu)
|
2008-11-10 |
2018-08-28 |
Arbutus Biopharma Corp |
Új lipidek és készítmények terápiás hatóanyagok szállítására
|
|
WO2010068866A2
(en)
|
2008-12-12 |
2010-06-17 |
Bind Biosciences |
Therapeutic particles suitable for parenteral administration and methods of making and using same
|
|
US20100216804A1
(en)
|
2008-12-15 |
2010-08-26 |
Zale Stephen E |
Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
|
|
WO2010080724A1
(en)
|
2009-01-12 |
2010-07-15 |
Merck Sharp & Dohme Corp. |
Novel lipid nanoparticles and novel components for delivery of nucleic acids
|
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
US20140141089A1
(en)
|
2009-02-11 |
2014-05-22 |
Colorado School Of Mines |
Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same
|
|
PT2414322T
(pt)
|
2009-03-20 |
2022-12-07 |
Egen Inc |
Derivados de poliamina
|
|
US8715736B2
(en)
|
2009-04-30 |
2014-05-06 |
Florida Agricultural And Mechanical University |
Nanoparticle formulations for skin delivery
|
|
KR20180094137A
(ko)
|
2009-05-05 |
2018-08-22 |
알닐람 파마슈티칼스 인코포레이티드 |
지질 조성물
|
|
AP2012006053A0
(en)
*
|
2009-06-02 |
2012-02-29 |
Brian Charles Keller |
Pure peg-lipid conjugates.
|
|
MX342785B
(es)
|
2009-06-10 |
2016-10-12 |
Alnylam Pharmaceuticals Inc |
Formulacion mejorada de lipido.
|
|
US8353800B2
(en)
|
2009-06-12 |
2013-01-15 |
Eaton Corporation |
Limited slip differential using face gears and a pinion housing
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
|
ES2613498T3
(es)
|
2009-07-01 |
2017-05-24 |
Protiva Biotherapeutics Inc. |
Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
|
|
WO2011017108A2
(en)
|
2009-07-27 |
2011-02-10 |
Auspex Pharmaceuticals, Inc. |
Cyclopropyl modulators of p2y12 receptor
|
|
EP2467357B1
(en)
|
2009-08-20 |
2016-03-30 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
US20120157500A1
(en)
|
2009-08-24 |
2012-06-21 |
Weikang Tao |
Jak inhibition blocks rna interference associated toxicities
|
|
US20120253032A1
(en)
|
2009-10-08 |
2012-10-04 |
Merck Sharp & Dohme Corporation |
Novel cationic lipids with short lipid chains for oligonucleotide delivery
|
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
|
HUE042177T2
(hu)
|
2009-12-01 |
2019-06-28 |
Translate Bio Inc |
Szteroidszármazék mRNS szállítására humán genetikai betegségekben
|
|
WO2011071860A2
(en)
|
2009-12-07 |
2011-06-16 |
Alnylam Pharmaceuticals, Inc. |
Compositions for nucleic acid delivery
|
|
US8357401B2
(en)
|
2009-12-11 |
2013-01-22 |
Bind Biosciences, Inc. |
Stable formulations for lyophilizing therapeutic particles
|
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Lipid particles for delivery of nucleic acids
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
US20130116419A1
(en)
|
2010-01-22 |
2013-05-09 |
Daniel Zewge |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
|
US9149432B2
(en)
|
2010-03-19 |
2015-10-06 |
Massachusetts Institute Of Technology |
Lipid vesicle compositions and methods of use
|
|
US8207290B2
(en)
|
2010-03-26 |
2012-06-26 |
Cerulean Pharma Inc. |
Methods and systems for generating nanoparticles
|
|
EP2558074B1
(en)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
US9254327B2
(en)
|
2010-05-10 |
2016-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
|
US8802863B2
(en)
|
2010-05-24 |
2014-08-12 |
Sirna Therapeutics, Inc. |
Amino alcohol cationic lipids for oligonucleotide delivery
|
|
US8748667B2
(en)
|
2010-06-04 |
2014-06-10 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
CN103079592B
(zh)
|
2010-07-01 |
2015-10-21 |
浦项工科大学校产学协力团 |
使用来自细胞的微泡治疗和诊断癌症的方法
|
|
HUE026646T2
(en)
|
2010-07-06 |
2016-07-28 |
Glaxosmithkline Biologicals Sa |
Preferred liposomes containing lipids of PKA value for delivery of RNA
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
RS63817B1
(sr)
|
2010-07-06 |
2023-01-31 |
Glaxosmithkline Biologicals Sa |
Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
|
|
CA2801523C
(en)
|
2010-07-30 |
2021-08-03 |
Curevac Gmbh |
Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EA201390145A1
(ru)
|
2010-08-20 |
2013-11-29 |
Серулин Фарма Инк. |
Конъюгаты, частицы, композиции и связанные с ними способы
|
|
ES2727583T3
(es)
|
2010-08-31 |
2019-10-17 |
Glaxosmithkline Biologicals Sa |
Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
|
|
PT3970742T
(pt)
|
2010-08-31 |
2022-06-27 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para entrega de arn codificador de imunogénio
|
|
RS63890B1
(sr)
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
US9549901B2
(en)
|
2010-09-03 |
2017-01-24 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
ES2888231T3
(es)
|
2010-09-20 |
2022-01-03 |
Sirna Therapeutics Inc |
Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
|
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
RU2013120302A
(ru)
|
2010-10-01 |
2014-11-20 |
Модерна Терапьютикс, Инк. |
Сконструированные нуклеиновые кислоты и способы их применения
|
|
JP2013545727A
(ja)
|
2010-10-21 |
2013-12-26 |
メルク・シャープ・アンド・ドーム・コーポレーション |
オリゴヌクレオチド送達用の新規低分子量カチオン性脂質
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
CA2824526C
(en)
|
2011-01-11 |
2020-07-07 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
|
CN102068701B
(zh)
|
2011-01-18 |
2012-11-07 |
沈阳药科大学 |
可断裂peg脂质衍生物在制剂中的应用
|
|
CA2825023A1
(en)
|
2011-01-26 |
2012-08-02 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
US10363309B2
(en)
|
2011-02-04 |
2019-07-30 |
Case Western Reserve University |
Targeted nanoparticle conjugates
|
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
|
EP2675918B1
(en)
|
2011-02-15 |
2017-11-08 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
CN102204920B
(zh)
|
2011-03-18 |
2013-03-20 |
海南本创医药科技有限公司 |
阿司匹林钠普伐他汀钠药物组合物固体制剂
|
|
WO2012129483A1
(en)
|
2011-03-24 |
2012-09-27 |
Novartis Ag |
Adjuvant nanoemulsions with phospholipids
|
|
EP2691101A2
(en)
|
2011-03-31 |
2014-02-05 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
WO2013158127A1
(en)
|
2012-04-16 |
2013-10-24 |
Molecular Transfer, Inc. |
Agents for improved delivery of nucleic acids to eukaryotic cells
|
|
KR20140041505A
(ko)
|
2011-04-29 |
2014-04-04 |
셀렉타 바이오사이언시즈, 인크. |
조절 b 세포 유도를 위한 관용원성 합성 나노운반체
|
|
ES2762224T3
(es)
|
2011-05-12 |
2020-05-22 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Liposomas que comprenden lípidos conjugados con polímero y usos relacionados
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
WO2012158736A1
(en)
|
2011-05-17 |
2012-11-22 |
modeRNA Therapeutics |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
CN103857387B
(zh)
|
2011-06-02 |
2017-03-15 |
加利福尼亚大学董事会 |
膜包封的纳米颗粒及使用方法
|
|
PL3586861T3
(pl)
|
2011-06-08 |
2022-05-23 |
Translate Bio, Inc. |
Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
|
|
EP3354644A1
(en)
|
2011-06-08 |
2018-08-01 |
Translate Bio, Inc. |
Cleavable lipids
|
|
CN102813929B
(zh)
|
2011-06-09 |
2014-04-09 |
沈阳药科大学 |
低浓度peg脂质衍生物及其应用
|
|
US20140141070A1
(en)
|
2011-07-06 |
2014-05-22 |
Andrew Geall |
Liposomes having useful n:p ratio for delivery of rna molecules
|
|
SG10201605512WA
(en)
|
2011-07-06 |
2016-09-29 |
Novartis Ag |
Oil-in-water emulsions that contain nucleic acids
|
|
US11058762B2
(en)
|
2011-07-06 |
2021-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
CA2840965C
(en)
|
2011-07-06 |
2021-03-02 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
WO2013006838A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
|
BR112014001829A2
(pt)
*
|
2011-08-11 |
2017-01-17 |
Stiefel Res Australia Pty Ltd |
composições tópicas antioxidantes
|
|
EP3508220A1
(en)
|
2011-08-31 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Pegylated liposomes for delivery of immunogen-encoding rna
|
|
US9126966B2
(en)
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
CA2845845A1
(en)
|
2011-08-31 |
2013-03-07 |
Mallinckrodt Llc |
Nanoparticle peg modification with h-phosphonates
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
EP2573086A1
(en)
*
|
2011-09-26 |
2013-03-27 |
AiCuris GmbH & Co. KG |
N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
|
|
EP2760477B1
(en)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
|
JP2014532071A
(ja)
|
2011-10-14 |
2014-12-04 |
エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ |
カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
|
|
JP6294229B2
(ja)
|
2011-10-18 |
2018-03-14 |
ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
アミン陽イオン性脂質およびその使用
|
|
CA2852857A1
(en)
|
2011-10-20 |
2013-04-25 |
Novartis Ag |
Adjuvanted influenza b virus vaccines for pediatric priming
|
|
EP3069785A1
(en)
|
2011-10-25 |
2016-09-21 |
The University Of British Columbia |
Limit size lipid nanoparticles and related methods
|
|
WO2013066903A1
(en)
|
2011-10-31 |
2013-05-10 |
Mallinckrodt Llc |
Combinational liposome compositions for cancer therapy
|
|
US9579338B2
(en)
|
2011-11-04 |
2017-02-28 |
Nitto Denko Corporation |
Method of producing lipid nanoparticles for drug delivery
|
|
WO2013067537A1
(en)
|
2011-11-04 |
2013-05-10 |
Univertiy Of Notre Dame Du Lac |
Nanoparticle-based drug delivery
|
|
CA2853685C
(en)
|
2011-11-04 |
2019-09-03 |
Nitto Denko Corporation |
Single use system for sterilely producing lipid-nucleic acid particles
|
|
BR112014013175B1
(pt)
|
2011-12-02 |
2022-08-09 |
Pegasus Laboratories, Inc |
Processo para preparar comprimidos de composição de liberação prolongada
|
|
US20140308304A1
(en)
|
2011-12-07 |
2014-10-16 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
EP2788316B1
(en)
|
2011-12-07 |
2019-04-24 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
EP2788006B1
(en)
|
2011-12-07 |
2026-01-07 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086526A1
(en)
|
2011-12-09 |
2013-06-13 |
The Regents Of The University Of California |
Liposomal drug encapsulation
|
|
CA2858694A1
(en)
|
2011-12-12 |
2013-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
Lipid nano particles comprising combination of cationic lipids
|
|
TWI594767B
(zh)
|
2011-12-12 |
2017-08-11 |
協和醱酵麒麟有限公司 |
含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子
|
|
US20140378538A1
(en)
|
2011-12-14 |
2014-12-25 |
Moderma Therapeutics, Inc. |
Methods of responding to a biothreat
|
|
WO2013090186A1
(en)
|
2011-12-14 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleic acids, and acute care uses thereof
|
|
WO2013087083A1
(en)
|
2011-12-15 |
2013-06-20 |
Biontech Ag |
Particles comprising single stranded rna and double stranded rna for immunomodulation
|
|
BR112014014599A2
(pt)
*
|
2011-12-16 |
2017-06-13 |
Massachusetts Inst Technology |
polímeros de alfa-aminoamidina e uso dos mesmos
|
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
|
JP2015510495A
(ja)
|
2011-12-21 |
2015-04-09 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
器官または器官移植片の生存可能性または寿命を延長する方法
|
|
WO2013116126A1
(en)
|
2012-02-01 |
2013-08-08 |
Merck Sharp & Dohme Corp. |
Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
KR102081560B1
(ko)
|
2012-02-09 |
2020-02-25 |
라이프 테크놀로지스 코포레이션 |
친수성 중합체성 입자 및 그의 제조 방법
|
|
US20130243867A1
(en)
|
2012-02-23 |
2013-09-19 |
University Of South Florida (A Florida Non-Profit Corporation) |
Micelle compositions and methods for their use
|
|
SG11201405157PA
(en)
|
2012-02-24 |
2014-10-30 |
Protiva Biotherapeutics Inc |
Trialkyl cationic lipids and methods of use thereof
|
|
US10322089B2
(en)
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
NZ631034A
(en)
|
2012-03-16 |
2016-06-24 |
Merck Patent Gmbh |
Targeting aminoacid lipids
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
WO2013148186A1
(en)
|
2012-03-26 |
2013-10-03 |
President And Fellows Of Harvard College |
Lipid-coated nucleic acid nanostructures of defined shape
|
|
WO2013148541A1
(en)
|
2012-03-27 |
2013-10-03 |
Merck Sharp & Dohme Corp. |
DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
|
|
HK1206644A1
(en)
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
AU2013243948A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
AU2013249548A1
(en)
|
2012-04-19 |
2014-11-06 |
Sirna Therapeutics, Inc. |
Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
AU2013256008B2
(en)
|
2012-05-04 |
2016-02-25 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
|
WO2013173693A1
(en)
|
2012-05-18 |
2013-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nanoparticles with enhanced entry into cancer cells
|
|
SI2858974T1
(sl)
|
2012-06-08 |
2019-01-31 |
Nitto Denko Corporation |
Lipidi za formulacije za dostavo terapevtskega sredstva
|
|
US10245229B2
(en)
|
2012-06-08 |
2019-04-02 |
Translate Bio, Inc. |
Pulmonary delivery of mRNA to non-lung target cells
|
|
WO2014008334A1
(en)
|
2012-07-06 |
2014-01-09 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
EP2882706A1
(en)
|
2012-08-13 |
2015-06-17 |
Massachusetts Institute of Technology |
Amine-containing lipidoids and uses thereof
|
|
WO2014026284A1
(en)
|
2012-08-14 |
2014-02-20 |
Froese Aaron |
Internal structured self assembling liposomes
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
WO2014093924A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
US20150202153A1
(en)
|
2012-10-04 |
2015-07-23 |
University Of The Witwatersrand, Johannesburg |
Liposomal drug delivery system
|
|
WO2014071072A2
(en)
|
2012-11-02 |
2014-05-08 |
Pungente Michael D |
Novel cationic carotenoid-based lipids for cellular nucleic acid uptake
|
|
US9669104B2
(en)
|
2012-11-07 |
2017-06-06 |
Council Of Scientific And Industrial Research |
Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules
|
|
WO2014081507A1
(en)
|
2012-11-26 |
2014-05-30 |
Moderna Therapeutics, Inc. |
Terminally modified rna
|
|
WO2014093574A1
(en)
|
2012-12-13 |
2014-06-19 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
HUE036815T2
(hu)
*
|
2012-12-21 |
2018-07-30 |
Syngenta Ltd |
Herbicidként aktív ciklusos dionvegyületek vagy származékaik, amelyek alkinilt tartalmazó szubsztituenssel rendelkezõ fenilcsoporttal helyettesítettek
|
|
EP2968391A1
(en)
|
2013-03-13 |
2016-01-20 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
DK2970456T3
(da)
|
2013-03-14 |
2021-07-05 |
Translate Bio Inc |
Fremgangsmåder og sammensætninger til levering af mrna-kodede antistoffer
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
CA2906732C
(en)
|
2013-03-15 |
2023-08-08 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
|
WO2014144711A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US10130649B2
(en)
|
2013-03-15 |
2018-11-20 |
Translate Bio, Inc. |
Synergistic enhancement of the delivery of nucleic acids via blended formulations
|
|
WO2014152027A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Manufacturing methods for production of rna transcripts
|
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
NO2753788T3
(https=)
*
|
2013-05-10 |
2018-06-16 |
|
|
|
KR102486617B1
(ko)
|
2013-05-22 |
2023-01-12 |
알닐람 파마슈티칼스 인코포레이티드 |
Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
|
|
US9895443B2
(en)
|
2013-06-26 |
2018-02-20 |
Massachusetts Institute Of Technology |
Multi-tailed lipids and uses thereof
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
SMT202100691T1
(it)
|
2013-07-11 |
2022-01-10 |
Modernatx Inc |
Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
CN103637988A
(zh)
|
2013-09-11 |
2014-03-19 |
浙江中医药大学 |
一种姜黄素长循环脂质体的制备方法
|
|
EP3043826A4
(en)
*
|
2013-09-13 |
2017-05-24 |
Moderna Therapeutics, Inc. |
Polynucleotide compositions containing amino acids
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015051169A2
(en)
|
2013-10-02 |
2015-04-09 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
US20170173128A1
(en)
|
2013-12-06 |
2017-06-22 |
Moderna TX, Inc. |
Targeted adaptive vaccines
|
|
ES2895651T3
(es)
|
2013-12-19 |
2022-02-22 |
Novartis Ag |
Lípidos y composiciones lipídicas para la administración de agentes activos
|
|
EP4019506A1
(en)
|
2013-12-19 |
2022-06-29 |
Novartis AG |
Lipids and lipid compositions for the delivery of active agents
|
|
US10821175B2
(en)
|
2014-02-25 |
2020-11-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
US20170143848A1
(en)
|
2014-03-24 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for the treatment of ocular diseases
|
|
SG10201912038TA
(en)
*
|
2014-04-23 |
2020-02-27 |
Modernatx Inc |
Nucleic acid vaccines
|
|
EP3134522B1
(en)
|
2014-04-25 |
2021-10-06 |
University of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
SMT202200502T1
(it)
|
2014-06-25 |
2023-01-13 |
Acuitas Therapeutics Inc |
Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
|
US10125092B2
(en)
|
2014-09-05 |
2018-11-13 |
Novartis Ag |
Lipids and lipid compositions for the delivery of active agents
|
|
CN104644555A
(zh)
|
2014-11-18 |
2015-05-27 |
中国科学院过程工程研究所 |
一种避免加速血液清除现象的长循环脂质体、制备方法及应用
|
|
SG11201705264WA
(en)
|
2014-12-31 |
2017-07-28 |
The Usa As Represented By The Secretary Detp Of Health And Human Services |
Novel multivalent nanoparticle-based vaccines
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016118725A1
(en)
|
2015-01-23 |
2016-07-28 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016145045A1
(en)
*
|
2015-03-11 |
2016-09-15 |
Peloton Therapeutics, Inc. |
Compositions for use in treating glioblastoma
|
|
US10278942B2
(en)
*
|
2015-03-11 |
2019-05-07 |
Peloton Therapeutics, Inc. |
Compositions for use in treating pulmonary arterial hypertension
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP3324979B1
(en)
|
2015-07-21 |
2022-10-12 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
WO2017019935A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Multimeric mrna
|
|
WO2017020026A1
(en)
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
EP4286012A3
(en)
|
2015-09-17 |
2024-05-29 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
WO2017070620A2
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
AU2016342049B2
(en)
|
2015-10-22 |
2023-05-18 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
MX2018004917A
(es)
|
2015-10-22 |
2019-04-01 |
Modernatx Inc |
Vacuna de virus sincitial respiratorio.
|
|
CA3002912A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
TW201729835A
(zh)
|
2015-10-22 |
2017-09-01 |
現代公司 |
呼吸道病毒疫苗
|
|
EP3364949A4
(en)
|
2015-10-22 |
2019-07-31 |
ModernaTX, Inc. |
CANCER VACCINES
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
IL307179A
(en)
*
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
|
HUE057877T2
(hu)
|
2015-12-22 |
2022-06-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
WO2017123616A1
(en)
|
2016-01-11 |
2017-07-20 |
Merrimack Pharmaceuticals, Inc. |
Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
MA45036A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
|
|
WO2017201352A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
KR20230074598A
(ko)
|
2016-05-18 |
2023-05-30 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
MA45032A
(fr)
|
2016-05-18 |
2019-03-27 |
Fundacion Para La Investig Medica Aplicada |
Polynucléotides codant pour la porphobilinogène désaminase destinés au traitement de la porphyrie intermittente aiguë
|
|
WO2017201348A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
KR102469450B1
(ko)
|
2016-05-18 |
2022-11-22 |
모더나티엑스, 인크. |
인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도
|
|
EP3458104A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
WO2017201347A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
AU2017266932B2
(en)
|
2016-05-18 |
2023-04-20 |
Modernatx, Inc. |
Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN116837052A
(zh)
|
2016-09-14 |
2023-10-03 |
摩登纳特斯有限公司 |
高纯度rna组合物及其制备方法
|
|
MA46584A
(fr)
|
2016-10-21 |
2019-08-28 |
Modernatx Inc |
Vaccin contre le cytomégalovirus humain
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
BR112019008481A2
(pt)
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
EP3532613A4
(en)
|
2016-10-26 |
2020-05-06 |
ModernaTX, Inc. |
METHOD AND COMPOSITIONS FOR RNA MAPPING
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
WO2018089801A1
(en)
|
2016-11-10 |
2018-05-17 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
WO2018089851A2
(en)
|
2016-11-11 |
2018-05-17 |
Modernatx, Inc. |
Influenza vaccine
|
|
WO2018107088A2
(en)
|
2016-12-08 |
2018-06-14 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
WO2018111967A1
(en)
|
2016-12-13 |
2018-06-21 |
Modernatx, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
JP2020514321A
(ja)
|
2017-02-01 |
2020-05-21 |
モデルナティーエックス， インコーポレイテッド |
活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
|
|
EP3576751A4
(en)
|
2017-02-01 |
2021-08-04 |
ModernaTX, Inc. |
RNA ANTI-CANCER VACCINES
|
|
WO2018144778A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Polynucleotide secondary structure
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
US20200368162A1
(en)
|
2017-02-24 |
2020-11-26 |
Modernatx, Inc. |
Nucleic Acid-Based Therapy of Muscular Dystrophies
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11969506B2
(en)
*
|
2017-03-15 |
2024-04-30 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
EP3595713A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
RESPIRATORY SYNCYTIAL VIRUS Vaccine
|
|
SMT202300097T1
(it)
|
2017-03-15 |
2023-05-12 |
Modernatx Inc |
Composto e composizioni per il rilascio intracellulare di agenti terapeutici
|
|
MA47790A
(fr)
|
2017-03-17 |
2021-05-05 |
Modernatx Inc |
Vaccins à base d'arn contre des maladies zoonotiques
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
|
MA49463A
(fr)
|
2017-04-26 |
2021-05-05 |
Modernatx Inc |
Vaccin contre le virus de l'herpès simplex
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
EP3655040A1
(en)
|
2017-07-21 |
2020-05-27 |
Modernatx, Inc. |
Modified mrna encoding a propionyl-coa carboxylase and uses thereof
|
|
WO2019036683A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
ANALYTICAL METHODS BY HPLC
|
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
MA50751A
(fr)
|
2017-08-18 |
2020-06-24 |
Modernatx Inc |
Vaccins à base d'arnm efficaces
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
CA3080592A1
(en)
|
2017-10-31 |
2019-05-09 |
Modernatx, Inc. |
Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
EP3713601A4
(en)
|
2017-11-21 |
2022-03-09 |
Modernatx, Inc. |
VACCINES AGAINST EPSTEIN-BARR VIRUS
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
CN113365639A
(zh)
|
2018-06-27 |
2021-09-07 |
摩登纳特斯有限公司 |
个性化癌症疫苗表位选择
|
|
WO2020056370A1
(en)
|
2018-09-13 |
2020-03-19 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
CN113271926A
(zh)
|
2018-09-20 |
2021-08-17 |
摩登纳特斯有限公司 |
脂质纳米颗粒的制备及其施用方法
|
|
CA3118947A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
JP7635131B2
(ja)
|
2019-01-31 |
2025-02-25 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
CN113795579A
(zh)
|
2019-02-20 |
2021-12-14 |
摩登纳特斯有限公司 |
用于共转录加帽的rna聚合酶变体
|
|
CA3132975A1
(en)
|
2019-03-11 |
2020-09-17 |
Modernatx, Inc. |
Fed-batch in vitro transcription process
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
AU2020283030A1
(en)
|
2019-05-31 |
2021-12-23 |
Modernatx, Inc. |
Expanded T cell assay
|
|
CN114269918A
(zh)
|
2019-08-14 |
2022-04-01 |
摩登纳特斯有限公司 |
用于纯化体外转录的下游产物的方法
|
|
CA3154082A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
AU2020350759A1
(en)
|
2019-09-19 |
2022-03-31 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
US20220349006A1
(en)
|
2019-09-19 |
2022-11-03 |
Moderna TX, Inc. |
Cap guides and methods of use thereof for rna mapping
|
|
WO2021055849A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4088281A4
(en)
|
2020-01-10 |
2024-02-21 |
ModernaTX, Inc. |
VARIOUS AUTOCECODER FOR GENERATING BIOLOGICAL SEQUENCE
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
CN115103682A
(zh)
|
2020-01-30 |
2022-09-23 |
摩登纳特斯有限公司 |
呼吸道病毒免疫组合物
|
|
US20230285297A1
(en)
|
2020-01-31 |
2023-09-14 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
JP7438604B2
(ja)
|
2020-02-07 |
2024-02-27 |
モデルナティエックス インコーポレイテッド |
ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
US20230181481A1
(en)
|
2020-05-15 |
2023-06-15 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating covid-19
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
WO2021237084A1
(en)
|
2020-05-21 |
2021-11-25 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
WO2021247817A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
|
KR20230087443A
(ko)
|
2020-08-06 |
2023-06-16 |
모더나티엑스, 인크. |
페이로드 분자를 기도 상피로 전달하기 위한 조성물
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4217371A1
(en)
|
2020-09-25 |
2023-08-02 |
ModernaTX, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
EP4277655A1
(en)
|
2021-01-15 |
2023-11-22 |
ModernaTX, Inc. |
Variant strain-based coronavirus vaccines
|
|
JP2024503699A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
バリアント株ベースのコロナウイルスワクチン
|
|
US20240100145A1
(en)
|
2021-03-05 |
2024-03-28 |
Moderna TX, Inc. |
Vlp enteroviral vaccines
|
|
EP4308156A1
(en)
|
2021-03-15 |
2024-01-24 |
ModernaTX, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
WO2022204491A1
(en)
|
2021-03-26 |
2022-09-29 |
Modernatx, Inc. |
Pertussis vaccine
|
|
WO2022212442A1
(en)
|
2021-03-31 |
2022-10-06 |
Modernatx, Inc. |
Synthesis of trinucleotide and tetranucleotide caps for mrna production
|
|
JP2024512780A
(ja)
|
2021-04-01 |
2024-03-19 |
モデルナティエックス インコーポレイテッド |
多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法
|
|
WO2022212191A1
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Mucosal expression of antibody structures and isotypes by mrna
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
WO2022221335A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
US20240207392A1
(en)
|
2021-04-13 |
2024-06-27 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|
|
JP2024513999A
(ja)
|
2021-04-14 |
2024-03-27 |
モデルナティエックス インコーポレイテッド |
インフルエンザ－コロナウイルス組み合わせワクチン
|
|
US20240238211A1
(en)
|
2021-04-23 |
2024-07-18 |
Modernatx, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
|
EP4326227A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Stabilized formulations
|
|
WO2022232585A1
(en)
|
2021-04-29 |
2022-11-03 |
Modernatx, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
EP4355761A1
(en)
|
2021-06-14 |
2024-04-24 |
ModernaTX, Inc. |
Mrna vaccines encoding flexible coronavirus spike proteins
|
|
US20240293534A1
(en)
|
2021-06-14 |
2024-09-05 |
Modernatx, Inc. |
Coronavirus glycosylation variant vaccines
|
|
US20240218353A1
(en)
|
2021-06-17 |
2024-07-04 |
Modernatx, Inc. |
Alternative rna purification strategies
|
|
WO2023283645A1
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus domain vaccines
|
|
WO2023283642A2
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus concatemeric vaccines
|
|
WO2023283651A1
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus vaccines
|
|
US20250092440A1
(en)
|
2021-08-02 |
2025-03-20 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
|
US20250281418A1
(en)
|
2021-08-11 |
2025-09-11 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
|
WO2023018923A1
(en)
|
2021-08-13 |
2023-02-16 |
Modernatx, Inc. |
Multicolumn chromatography mrna purification
|
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
|
JP2024540917A
(ja)
|
2021-10-18 |
2024-11-06 |
モデルナティエックス インコーポレイテッド |
組み換えタンパク質生産のためのカスタム株
|
|
WO2023069895A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Markerless dna production
|
|
WO2023069625A1
(en)
|
2021-10-20 |
2023-04-27 |
Modernatx, Inc. |
Drug product surrogate solutions
|
|
US20250362278A1
(en)
|
2021-11-01 |
2025-11-27 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
|
EP4426855A1
(en)
|
2021-11-05 |
2024-09-11 |
ModernaTX, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
EP4444345A2
(en)
|
2021-12-08 |
2024-10-16 |
ModernaTX, Inc. |
Herpes simplex virus mrna vaccines
|
|
US20250067729A1
(en)
|
2021-12-15 |
2025-02-27 |
ModrnaTX, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
|
WO2023132885A1
(en)
|
2022-01-04 |
2023-07-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023137149A1
(en)
|
2022-01-14 |
2023-07-20 |
Modernatx, Inc. |
In vitro transcription dna purification and recycling
|
|
JP2025506416A
(ja)
|
2022-02-03 |
2025-03-11 |
モデルナティエックス インコーポレイテッド |
ｍＲＮＡ精製のための連続的沈殿
|
|
WO2023154818A1
(en)
|
2022-02-09 |
2023-08-17 |
Modernatx, Inc. |
Mucosal administration methods and formulations
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
EP4508242A1
(en)
|
2022-04-11 |
2025-02-19 |
ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
US20250250551A1
(en)
|
2022-04-14 |
2025-08-07 |
Modernatx, Inc. |
Rna polymerase variants
|
|
EP4508069A1
(en)
|
2022-04-15 |
2025-02-19 |
ModernaTX, Inc. |
Ribosomal engagement potency assay
|
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
|
EP4525830A1
(en)
|
2022-05-17 |
2025-03-26 |
ModernaTX, Inc. |
Preparation of highly concentrated mrna
|
|
WO2023250119A1
(en)
|
2022-06-24 |
2023-12-28 |
Modernatx, Inc. |
Methods of producing rna
|
|
WO2024010993A1
(en)
|
2022-07-06 |
2024-01-11 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
WO2024026005A1
(en)
|
2022-07-28 |
2024-02-01 |
Modernatx, Inc. |
Methods of rna purification
|
|
EP4565694A1
(en)
|
2022-08-01 |
2025-06-11 |
ModernaTX, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
EP4612301A1
(en)
|
2022-11-03 |
2025-09-10 |
ModernaTX, Inc. |
Chemical stability of mrna
|
|
WO2024123978A1
(en)
|
2022-12-08 |
2024-06-13 |
Modernatx, Inc. |
Ionizable lipids with malonate tails
|
|
EP4648793A1
(en)
|
2023-01-11 |
2025-11-19 |
ModernaTX, Inc. |
Personalized cancer vaccines
|
|
WO2024163465A1
(en)
|
2023-01-30 |
2024-08-08 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|
|
JP2026509266A
(ja)
|
2023-03-10 |
2026-03-17 |
モデルナティエックス インコーポレイテッド |
核酸インフルエンザワクチン及び呼吸器ウイルス混合ワクチン
|
|
WO2024206835A1
(en)
|
2023-03-30 |
2024-10-03 |
Modernatx, Inc. |
Circular mrna and production thereof
|
|
WO2024215721A1
(en)
|
2023-04-10 |
2024-10-17 |
Modernatx, Inc. |
Lyme disease vaccines
|